SCHEMBL4509983

SCHEMBL4509983

NCC1CCN(Cc2cccc3ccccc23)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.68
CXCR4 P61073 1/20 0.66
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
HTR2B P41595 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TSHR P16473 1/20 0.55
SLC6A4 P31645 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
OPRL1 P41146 3/20 0.50
OPRM1 P35372 2/20 0.50
OPRK1 P41145 2/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947115 0.84 ACHE (0.72) ACHEHTR2AHTR2CHTR2BSIGMAR1
SCHEMBL14193587 0.84 CXCR4 (0.53) ACHECXCR4MEN1KMT2AOPRL1
SCHEMBL29767427 0.80 CXCR4 (1.00) CXCR4SIGMAR1MEN1KMT2A
SCHEMBL31392633 0.79 ACHE (0.68) ACHEMEN1KMT2ATSHRHDAC1
SCHEMBL3921135 0.79 ACHE (0.68) ACHEMEN1KMT2ATSHROPRL1
SCHEMBL29767426 0.78 CXCR4 (0.69) ACHECXCR4MEN1KMT2A
SCHEMBL29767452 0.78 CXCR4 (0.69) CXCR4SIGMAR1MEN1KMT2AOPRK1
SCHEMBL22444298 0.78 CXCR4 (0.69) ACHECXCR4SIGMAR1TSHRBCHE
SCHEMBL23750981 0.78 ACHE (0.59) ACHETSHROPRL1DRD2DRD4
SCHEMBL13202838 0.78 ACHE (0.71) ACHEHTR2AHTR2CHTR2BSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1502916-A1 PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 ACHE 4551/4885CXCR4 44/4885HTR2A 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.